Monotherapy with Mood Stabilizers Versus Atypical Antipsychotics for the Treatment of Bipolar Disorder in Children and Adolescents PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Monotherapy with Mood Stabilizers Versus Atypical Antipsychotics for the Treatment of Bipolar Disorder in Children and Adolescents PDF full book. Access full book title Monotherapy with Mood Stabilizers Versus Atypical Antipsychotics for the Treatment of Bipolar Disorder in Children and Adolescents by Sonam Mehta. Download full books in PDF and EPUB format.
Author: Sonam Mehta
Publisher:
ISBN:
Category : Manic-depressive illness in children
Languages : en
Pages : 132
Get Book Here
Book Description
Author: Sonam Mehta
Publisher:
ISBN:
Category : Manic-depressive illness in children
Languages : en
Pages : 132
Get Book Here
Book Description
Author: Barbara Geller
Publisher: Guilford Press
ISBN: 1593856784
Category : Psychology
Languages : en
Pages : 433
Get Book Here
Book Description
Recent advances in evidence-based treatment of pediatric bipolar disorder are reviewed in this authoritative volume. The editors and contributors examine the current status of medications and psychosocial therapies, and explore new horizons in tailoring treatment to individuals' neurobiological and clinical profiles.
Author: Robert L. Findling
Publisher: CRC Press
ISBN: 9781841840543
Category : Medical
Languages : en
Pages : 180
Get Book Here
Book Description
Bipolar disorders were once considered rare in children and adolescents. A growing body of scientific evidence now suggests that they may be more prevalent in this group than previously believed. At the same time, the practitioner faces significant clinical challenges in both the assessment processes and also the implementation of a treatment plan. A paucity of treatment manuals and pharmacological algorithms providing practical guidance makes the task of the clinician even more difficult, despite the fact that more is known about the assessment, neurobiology and treatment of children and adolescents with bipolar disorder than ever before. Written by three distinguished experts, this book conveys to clinicians all the information currently available in this area. They review both the neuroscience and also the integration of rational, practical, pharmacological and psychosocial interventions. Based on what is known, a sound approach to the assessment of these youngsters can be developed. Similarly, available evidence allows practitioners to ground their treatment protocols solidly on scientific knowledge. Concise and authoritative, Pediatric Bipolar Disorders will give the reader a practical approach to both the art and science of providing the best possible clinical care to children and adolescents with the disorder. This book is written primarily for clinical psychiatrists, but will also be of interest to non-specialist doctors and other members of the health care team.
Author: Mary A. Fristad
Publisher: Guilford Press
ISBN: 1609182014
Category : Psychology
Languages : en
Pages : 449
Get Book Here
Book Description
"Packed with ready-to-use clinical tools, this book presents the first evidence-based psychosocial treatment for school-age children with bipolar disorder or depression. Leading clinician/researcher Mary Fristad and her colleagues show how to integrate psychoeducational strategies with cognitive-behavioral and family therapy techniques. They provide nuts-and-bolts information for implementing the approach with individual families or groups. Kids learn to identify and manage mood states while parents learn essential skills for problem solving, crisis management, improving family functioning, and collaborating with schools and mental health systems. In a large-size format with lay-flat binding for easy photocopying, the book features over 75 reproducible handouts and 20 children's game materials"--Provided by publisher.
Author: Demitri Papolos, M.D.
Publisher: Harmony
ISBN: 0767928601
Category : Psychology
Languages : en
Pages : 498
Get Book Here
Book Description
Since it first appeared on bookshelves, The Bipolar Child has made an indelible mark on the field of psychiatry and has become the resource that families rely upon. Now, with more than 200,000 copies sold, the first book about early-onset bipolar disorder is completely revised and expanded. Bipolar disorder—manic depression—was once thought to be rare in children. Now researchers are discovering not only that bipolar disorder can begin early in life, but that it is much more common than ever imagined. Yet the illness is often misdiagnosed and mistreated with medications that can exacerbate the symptoms. Why? Bipolar disorder manifests itself differently in children than in adults, and in children there is an overlap of symptoms with other childhood psychiatric disorders. As a result, these kids may be labeled with any of a number of psychiatric conditions: “ADHD,” “depression,” “oppositional defiant disorder,” “obsessive-compulsive disorder,” or “generalized anxiety disorder.” Too often they are treated with stimulants or antidepressants—medications that can actually worsen the bipolar condition. Since the publication of its first edition, The Bipolar Child has helped many thousands of families get to the root cause of their children’s behaviors and symptoms and find what they need to know. The Papoloses comprehensively detail the diagnosis, explain how to find good treatment and medications, and advise parents about ways to advocate effectively for their children in school. In this edition, a greatly expanded education chapter describes all the changes in educational law due to the 2004 reauthorization of IDEA (Individuals with Disabilities Education Act), and offers a multitude of ideas for parents and educators to help the children feel more comfortable in the academic environment. The book also contains crucial information about hospitalization, the importance of neuropsychological testing (with a recommended battery of tests), and the world of insurance. Included in these pages is information on promising new drugs, greater insight into the special concerns of teenagers, and additional sections on the impact of the illness on the family. In addition, an entirely new chapter focuses on major advances taking place in the field of molecular genetics and offers hope that researchers will better understand the illness and develop more targeted and easier-to-tolerate medicines. The Bipolar Child is rich with the voices of parents, siblings, and the children themselves, opening up the long-closed world of the families struggling with this condition. This book has already proved to be an invaluable resource for parents whose children suffer from mood disorders, as well as for the professionals who treat and educate them, and this new edition is sure to continue to light the way.
Author: Yonghua Jing
Publisher:
ISBN:
Category :
Languages : en
Pages : 165
Get Book Here
Book Description
Background: Pediatric bipolar disorder (PBD) is a severe, chronic illness and it is a significant cause of suffering and disability. Atypical antipsychotics are commonly used to treat PBD, but the economic and health outcomes of atypical antipsychotic treatment have been extraordinarily understudied. Major objectives for this dissertation are to evaluate the evolving pattern of drug utilization in children and adolescents with bipolar disorder (BD) and to assess the difference in health care utilization and costs between children and adolescents treated with and without atypical antipsychotics. Methods: The study design was a retrospective cohort data analysis of the PharMetrics, a large longitudinal national managed care claims database from 1998 to 2002. The study population included 19,325 youths (7̲age̲18) with a bipolar diagnosis indicated by ICD9 codes. Of those, a total of 488 patients who received atypical antipsychotic (ATYP) monotherapy treatment, 1784 patients who received mood stabilizer (MS) monotherapy treatment, and 1182 patients who received atypical antipsychotic-mood stabilizer (ATYP-MS) combination therapy were identified. Propensity scores were used to control for the selection bias inherent in drug treatment selection. Six months of follow-up health care utilization and costs data were compared between propensity-score matched groups using paired t-tests. Results: The prevalence of atypical antipsychotic use increased from 13.23 prescriptions per 100 recipients per quarter to 63.12 prescriptions per 100 recipients per quarter during the study period. Compare to MS monotherapy subjects, ATYP monotherapy subjects had fewer bipolar-related physician office visits (p=0.0093) and bipolar-related outpatient hospitalization visits (p=0.034) but similar bipolar-related days of hospitalization (p=0.24), and bipolar-related emergency department visits (p=0.23). ATYP-MS combination therapy subjects had more health utilization like bipolar-related physician office visits (p
Author: Demitri Papolos, M.D.
Publisher: Harmony
ISBN: 0767929268
Category : Psychology
Languages : en
Pages : 498
Get Book Here
Book Description
Since it first appeared on bookshelves, The Bipolar Child has made an indelible mark on the field of psychiatry and has become the resource that families rely upon. Now, with more than 200,000 copies sold, the first book about early-onset bipolar disorder is completely revised and expanded. Bipolar disorder—manic depression—was once thought to be rare in children. Now researchers are discovering not only that bipolar disorder can begin early in life, but that it is much more common than ever imagined. Yet the illness is often misdiagnosed and mistreated with medications that can exacerbate the symptoms. Why? Bipolar disorder manifests itself differently in children than in adults, and in children there is an overlap of symptoms with other childhood psychiatric disorders. As a result, these kids may be labeled with any of a number of psychiatric conditions: “ADHD,” “depression,” “oppositional defiant disorder,” “obsessive-compulsive disorder,” or “generalized anxiety disorder.” Too often they are treated with stimulants or antidepressants—medications that can actually worsen the bipolar condition. Since the publication of its first edition, The Bipolar Child has helped many thousands of families get to the root cause of their children’s behaviors and symptoms and find what they need to know. The Papoloses comprehensively detail the diagnosis, explain how to find good treatment and medications, and advise parents about ways to advocate effectively for their children in school. In this edition, a greatly expanded education chapter describes all the changes in educational law due to the 2004 reauthorization of IDEA (Individuals with Disabilities Education Act), and offers a multitude of ideas for parents and educators to help the children feel more comfortable in the academic environment. The book also contains crucial information about hospitalization, the importance of neuropsychological testing (with a recommended battery of tests), and the world of insurance. Included in these pages is information on promising new drugs, greater insight into the special concerns of teenagers, and additional sections on the impact of the illness on the family. In addition, an entirely new chapter focuses on major advances taking place in the field of molecular genetics and offers hope that researchers will better understand the illness and develop more targeted and easier-to-tolerate medicines. The Bipolar Child is rich with the voices of parents, siblings, and the children themselves, opening up the long-closed world of the families struggling with this condition. This book has already proved to be an invaluable resource for parents whose children suffer from mood disorders, as well as for the professionals who treat and educate them, and this new edition is sure to continue to light the way.
Author:
Publisher:
ISBN:
Category :
Languages : en
Pages : 6
Get Book Here
Book Description
Bipolar disorder is a mental condition characterized by episodic mood swings between euphoric or irritable mania and hopeless depression which can affect social activities, functioning, and relationships. Episodes are typically followed by symptom-free periods referred to as euthymia. According to a survey conducted in 2002, one percent (1%) of Canadians 15 years and older demonstrated symptoms satisfying the criteria for bipolar disorder in the previous 12 months. Multiple types of bipolar disorders exist such as bipolar I, bipolar II and are defined in the Diagnostic and Statistical Manual (5th edition; DSM-V) from the American Psychiatric Association. Symptoms associated with mania can include increased creativity and productivity; however, mania can also lead to immediate hospitalization or involuntary committal under the Mental Health Act. Symptoms associated with depression can lead to increased rates of suicide and suicide ideation. Bipolar disorder with psychotic features refers to manic or depressive episodes including psychotic symptoms such as delusions or hallucinations. Psychotic features manifest in over 50% of manic episodes and are more common in the latter than in depressive episodes. Pharmacological treatment usually depends on the type of bipolar disorder (manic or depressive); however, the most common treatments include lithium and valproic acid. Antipsychotic medications are also used to treat bipolar disorder and can be classified as typical (first generation) or atypical (second generation). First generation antipsychotics mitigate bipolar disorder symptoms by antagonizing dopamine D2 receptors, while second generation antipsychotics have an affinity for serotonin 5-hydroxytryptamine receptors and adrenergic receptors in addition to being D2 receptor antagonists. Atypical antipsychotics, such as aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone can be prescribed as monotherapy or in combination with mood stabilizers and antidepressants, as well as other treatment options. Although combinations of atypical antipsychotics have been used for the treatment of other disorders, such as schizophrenia, the effectiveness of combination therapy in bipolar disorder is unclear. This Rapid Response report aims to review the clinical and cost-effectiveness of combination atypical antipsychotics in adolescents or adults with bipolar disorder with psychotic features. Guidelines associated with the use of combination atypical antipsychotics in adolescents or adults with bipolar disorder with psychotic features will also be examined.
Author: Barbara Geller
Publisher: Guilford Press
ISBN: 9781593852931
Category : Psychology
Languages : en
Pages : 342
Get Book Here
Book Description
This volume provides a state-of-the-science review of knowledge on bipolar disorder in children, covering all aspects of theory and research. Leading clinical researchers address such topics as epidemiology, diagnosis and assessment, comorbidity, and outcomes. Compelling findings are presented on the neurobiological and genetic bases of the disorder. Throughout, contributors identify promising directions for further investigation while weighing in on key methodological questions and areas of controversy.
Author: Debajyoti Bhowmik
Publisher:
ISBN:
Category : Pharmacy management
Languages : en
Pages :
Get Book Here
Book Description
Pediatric bipolar disorder (I and II) patients suffer from recurrent episodes of depression and mania or hypomania (American Psychiatric Association, 1994), or mixed episodes with rapid cycling (Findling et al., 2001; Geller et al., 2002). Worldwide prevalence of bipolar disorder was 5% (Tondo et al., 2003), and in the USA was 2.6% in adults and 0-3% in adolescents (Bipolar Disorder). Early-onset bipolar disorder in childhood was associated with a higher number of lifetime episodes of manic and depressive phases, more comorbidities such as anxiety and substance abuse, rapid cycling between different phases, and higher incidence of suicide attempts compared to adulthood onset of bipolar disorder (Potter et al., 2009; Leverich et al., 2007; Perlis et al., 2004). Lifetime prevalence of the depressive phase among bipolar disorder patients is 3-fold higher than the mania phase (Post et al., 2003). Untreated bipolar depression among all the phases of bipolar disorder, particularly in children and adolescents, is associated with a high risk of suicidality (Tondo et al., 1998), substance abuse, functional disability, and poor academic and social performance among children and adolescents (Baldessarini et al., 2008; Angst et al., 2002; Frye et al., 2006; Thase, 2006; Dutta et al., 2007; Huxley and Baldessarini, 2007; Tondo and Baldessarini, 2007). Despite a higher prevalence of the depressive phase and associated risk of morbidity and mortality among bipolar disorder patients, research on the bipolar depressive phase is limited (Bhangoo et al., 2003). Although medication regimens includingmood stabilizers, antidepressants, and antipsychotics for treating bipolar depression in adults is well established (Lin et al., 2006), similar treatment guidelines for bipolar depression in younger populations are unavailable. Efficacy of different classes of medications in treating pediatric bipolar depression has been examined in several randomized trials or observational studies and documented (Kowatch et al., 2005), but psychiatric practice for children and adolescents in this regard is mostly extrapolated from adult guideline, expert consensus, or clinicians' experience. Accordingly, mood stabilizers and second-generation antipsychotics (SGA) are considered to be the 1st line therapy for pediatric bipolar depression, while antidepressants selective serotonin reuptake inhibitors (SSRI) and bupropion are recommended only as adjunct therapy when 1st line treatment is ineffective (Kowatch et al., 2005). However, the utilization pattern of medications in treating bipolar depression in pediatric population is mostly unexplored. Subsequently, real-world safety and effectiveness of psychotropic medications in pediatric bipolar depression is also limited. Controversy prevails over the safety of using antidepressants in bipolar depression patients due to the concerns about possible manic or hypomanic switching, rapid cycling, and long-term mood destabilization. Although a potential risk of mood destabilization with the use of antidepressants has been suggested historically, critical evaluation of those clinical trials suggested presence of bias and a lack of control groups to accurately address the issue. Quantitative real-world data on comparative safety of antidepressants, antipsychotics, and mood stabilizers, in terms of risk of short-term manic switch among pediatric bipolar depression patients, is limited as well. Effectiveness of psychotropic pharmacotherapy in bipolar disorder is examined for outcomes such as response, remission, recovery, and relapse of the depressive phase. Such outcomes are measured using mania and depression rating scales, such as Young's mania rating scale, Montgomery-Asberg depression rating scale, etc. Unavailability of such severity scales in administrative data hinders direct assessment of comparative effectiveness of psychotropic medications in real-world patients. Overall, numerical data on comparative effectiveness of antidepressants, antipsychotics, and mood stabilizers in pediatric bipolar depression is limited. Considering the prevalence of bipolar depression among children and adolescents and the associated risk of morbidity and mortality, and paucity of knowledge regarding drug utilization pattern, and comparative safety and effectiveness of antidepressant pharmacotherapy in this patient population, the specific aims of this study will be- Aim I: To assess adherence to psycho-pharmacotherapeutic regimens during 6 months after the initial bipolar depression diagnosis among Medicaid-enrolled children and adolescents, in terms of- (1) Continuation of antidepressant monotherapy, antipsychotic monotherapy, mood stabilizer monotherapy, antidepressant polytherapy (with antipsychotic or mood stabilizer), antipsychotic-mood stabilizer polytherapy, and 3-class polytherapy regimens during 6 months after initial bipolar depression diagnosis, (2) Augmentation pattern with a new class of medications among antidepressant, antipsychotic, and mood stabilizer monotherapy; and antidepressant, and antipsychotic-mood stabilizer polytherapy regimens during the 6 months of follow up after initial bipolar depression diagnosis, (3) Switch from initial treatment regimen including antidepressant, antipsychotic, and mood stabilizer monotherapy; and antidepressant, antipsychotic-mood stabilizer, and 3-class polytherapy to regimens inclusive of other therapeutic classes, during the 6 months of follow up after initial bipolar depression diagnosis, (4) All medication class discontinuation patterns in antidepressant, antipsychotic, and mood stabilizer monotherapy; and antidepressant, antipsychotic-mood stabilizer, and 3-class polytherapy regimens, during 6 the months of follow up after initial bipolar depression diagnosis. Aim II: To examine the risk of manic switch with the use of antidepressant in Medicaid-enrolled pediatric bipolar depression patients - (1) To assess comparative safety of antidepressant monotherapy against antipsychotic monotherapy, in terms of risk of manic switch in pediatric bipolar depression population, (2) To assess comparative safety of antidepressant monotherapy against mood stabilizer monotherapy, in terms of risk of manic switch in pediatric bipolar depression population, (3) To assess comparative safety of antidepressant polytherapy against antipsychotic-mood stabilizer polytherapy, in terms of risk of manic switch in pediatric bipolar depression population. Aim III: To evaluate the effectiveness of antidepressant pharmacotherapy among Medicaid enrolled children and adolescents with bipolar depression - (1) To assess risk of treatment augmentation in pediatric bipolar depression patients, comparing (i) Antidepressant monotherapy vs. antipsychotic monotherapy, (ii) Antidepressant monotherapy vs. mood stabilizer monotherapy, (iii) Antidepressant polytherapy vs. antipsychotic-mood stabilizer polytherapy. (2) To assess risk of mental-health related hospitalization in pediatric bipolar depression patients, comparing (i) Antidepressant monotherapy vs. antipsychotic monotherapy, (ii) Antidepressant monotherapy vs. mood stabilizer monotherapy, (iii) Antidepressant polytehrapy vs. antipsychotic-mood stabilizer polytherapy
